News | June 15, 2022
CCI approves sale of biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Researchers have developed a plasma-based disinfectant generated with the help of cold atmospheric pressure plasma (CAP) which could act as a green decontaminant for Covid-19
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Subscribe To Our Newsletter & Stay Updated
